These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 34175104)
1. My Treatment Approach to Clostridioides difficile Infection. Khanna S Mayo Clin Proc; 2021 Aug; 96(8):2192-2204. PubMed ID: 34175104 [TBL] [Abstract][Full Text] [Related]
2. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day! Khanna S J Intern Med; 2021 Aug; 290(2):294-309. PubMed ID: 33856727 [TBL] [Abstract][Full Text] [Related]
3. Therapeutics for Khanna S; Voth E Expert Rev Gastroenterol Hepatol; 2023; 17(9):903-911. PubMed ID: 37606962 [TBL] [Abstract][Full Text] [Related]
4. Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies. Berry P; Khanna S BioDrugs; 2023 Nov; 37(6):757-773. PubMed ID: 37493938 [TBL] [Abstract][Full Text] [Related]
5. Treatment of Oksi J; Anttila VJ; Mattila E Ann Med; 2020; 52(1-2):12-20. PubMed ID: 31801387 [No Abstract] [Full Text] [Related]
6. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials. Madoff SE; Urquiaga M; Alonso CD; Kelly CP Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500 [TBL] [Abstract][Full Text] [Related]
7. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Rokkas T; Gisbert JP; Gasbarrini A; Hold GL; Tilg H; Malfertheiner P; Megraud F; O'Morain C United European Gastroenterol J; 2019 Oct; 7(8):1051-1063. PubMed ID: 31662862 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease. You JHS; Jiang X; Lee WH; Chan PKS; Ng SC J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248 [TBL] [Abstract][Full Text] [Related]
11. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection. Hvas CL; Dahl Jørgensen SM; Jørgensen SP; Storgaard M; Lemming L; Hansen MM; Erikstrup C; Dahlerup JF Gastroenterology; 2019 Apr; 156(5):1324-1332.e3. PubMed ID: 30610862 [TBL] [Abstract][Full Text] [Related]
12. Clostridioides Difficile: A Concise Review of Best Practices and Updates. Yakout A; Bi Y; Harris DM J Prim Care Community Health; 2024; 15():21501319241249645. PubMed ID: 38726585 [TBL] [Abstract][Full Text] [Related]
13. Update of treatment algorithms for Clostridium difficile infection. Ooijevaar RE; van Beurden YH; Terveer EM; Goorhuis A; Bauer MP; Keller JJ; Mulder CJJ; Kuijper EJ Clin Microbiol Infect; 2018 May; 24(5):452-462. PubMed ID: 29309934 [TBL] [Abstract][Full Text] [Related]
14. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389 [TBL] [Abstract][Full Text] [Related]
15. Fecal microbiota transplantation (FMT) for C. difficile infection, just say 'No'. Tan X; Johnson S Anaerobe; 2019 Dec; 60():102092. PubMed ID: 31472233 [TBL] [Abstract][Full Text] [Related]